Iscartrelvir is an investigational new drug developed by the Westlake University for the treatment of COVID-19. It targets the SARS-CoV-2 3CL protease, which is crucial for the replication of the virus responsible for COVID-19.[1][2]

See also

References

  1. ^ Yang L, Wang Z (September 2023). "Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China". European Journal of Medicinal Chemistry. 257: 115503. doi:10.1016/j.ejmech.2023.115503. PMC 10193775. PMID 37229831.
  2. ^ Hou N, Shuai L, Zhang L, Xie X, Tang K, Zhu Y, et al. (February 2023). "Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro". ACS Central Science. 9 (2): 217–227. doi:10.1021/acscentsci.2c01359. PMC 9885526. PMID 36844503.


Allikas: http://en.wikipedia.org/wiki/Iscartrelvir
No tags for this post.